ONKURE THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
ONKURE THERAPEUTICS, INC. (OKUR) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -1.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-12
- ONKURE THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -1.50%.
- ONKURE THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -0.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | -1.50% 10-K · filed 2026-03-12 |
| 2024-12-31 | -0.40% 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |